Physicochemical and physiological considerations for efficient nose-to-brain targeting

Expert Opinion on Drug Delivery

Volumn 9, Issue 1, 2012, Pages 19-31

  Bahadur, Shiv ^a   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy   (India)

Author keywords

Brain targeting; Intranasal administration; Physicochemical properties; Physiological factors; Strategies

Indexed keywords

AMINO ACID; APROTININ; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZAPINE; CLOZAPINE DERIVATIVE; ENKEPHALIN; ESTRADIOL; HORMONE; HUMAN GROWTH HORMONE; LEUCINE; NIMODIPINE; OLANZAPINE; PROTEIN; RISPERIDONE; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

BRAIN; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; LIPOPHILICITY; MOLECULAR WEIGHT; NONHUMAN; OSMOLARITY; PARTITION COEFFICIENT; PH; PHYSICAL CHEMISTRY; REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NASAL MUCOSA; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PHENOMENA; TISSUE DISTRIBUTION;

EID: 84255182650     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.636801     Document Type: Review

References (65)

1. Chugh Y, Kapoor P, Kapoor AK. Intranasal drug delivery: a novel approach. Ind J Otolaryngol Head Neck Surg 2009;61:90-4
2. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9:1-5
3. Jain R, Nabar S, Dandekar P, et al. Micellar nanocarriers: Potentail nose-to- brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 2010;29(4):655-64
4. Dsuza R, Mutalik S, Venkatesh M, et al. Nasal insulin gel as an alternative to parenteral insulin: formulation preclinical and clinical studies. AAPS PharmSciTech 2005;6:184-90
5. Ugwoke MI, Agu RU, Verbeke N, et al. Nasal mucoadhesive drug delivery: bachground, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-65 (Pubitemid 41443473)
6. Wang D, Gao Y, Yan L. Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 2005;57:97-104
7. Talegaonkar S, Misra PR. Intranasal delivery: An approach to bypass the blood brain barrier. Ind J Pharmacol 2004;36(1):140-7 (Pubitemid 38787065)
8. Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery; How, why and what for. J Pharm Pharm Sci 2009;12(3):288-311
9. Wermeling DP. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009;6(2):352-8
10. Kumar M, Mishra A, Babbar AK, et al. Intranasal nanoemulsion based brain targetting drug delivery system of resperidone. Int J Pharm 2008;358:285-91
11. Chopra K, Misra S, Kuhad A. Neurological aspects of Alzheimers disease. Expert Opin Ther Targets 2011;15(5):535-55
12. Alam MA, Bega S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40:385-403
13. Kumar M, Mishra A, Pathak K. Formulation and characterization of nanoemulsion-based drug delivery system of resperidone. Drug Dev Ind Pharm 2009;35:387-95
14. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Deliv Tech 2002;7:67-97(18)5
15. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physiochemical and therapeutic aspects. Int J Pharm 2007;337:1-24 (Pubitemid 46756063)
16. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003;87:187-98 (Pubitemid 36255456)
17. Yang J, Liu H, Cheng S, et al. Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 2009;449:108-11
18. Illum L. Transport of drugs from nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18 (Pubitemid 30410839)
19. Arvizo R, Bhattacharya R, Mukherjee G. Gold nanoparticles opportunity and challenged in nanomedicine. Expert Opin Drug Deliv 2011;7(6):753-63
20. Khan S, Patil K, Yeole P, et al. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats. J Pharm Pharmacol 2009;61(5):669-75
21. Jadhav KR, Gambhire MN, Shaikh IM, et al. Nasal drug delivery system-factors affecting and applications. Curr Drug Ther 2007;2:27-38 (Pubitemid 46723136)
22. Behl CR, Pimplaskar HK, Sileno AP, et al. Effects of physicochemical properties and other factors on nasal drug delivery. Adv Drug Deliv Rev 1998;29:89-116 (Pubitemid 28044088)
23. Laquintana V, Trapani A, Denora N, et al. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 2009;6(10):1017-32
24. Turker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004;26:137-42 (Pubitemid 39012580)
25. Kimura R, Miwa M, Kato Y, et al. Nasal absorption of tetraethylammonium in rats. Arch Int Pharmacodyn Ther 1989;302:7-17 (Pubitemid 20210259)
26. Harikarnpakdee S, Lipipun V, Sutanthavibul N, et al. Spray dried mucoadhesive microspheres preparation and transport through nasal cell monolayer. AAPS PharmSciTech 2006;7:1-10
27. Ozsoy Y, Gungor S, Cevher L. Nasal delivery of high molecular weight drugs. Molecules 2009;14:3754-79
28. Henkin RI. Intranasal insulin: From nose to brain. Nutrition 2010;26:624-33
29. Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol 2000;45:432-4 (Pubitemid 30217170)
30. Illum L, Hinchelife M, David SS. The effect of blood sampling site and physicochemical characteristics of drugs on bioavailability of drugs on administration in the sheep model. Pharm Res 2003;20:1474-85
31. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharm Ther 2004;104:29-45 (Pubitemid 39410561)
32. Illum L. The nasal delivery of peptides and proteins. Trends Biotech 1991;9:284-9 (Pubitemid 121003123)
33. Yu H, Kim K. Direct nose -to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits. Int J Pharm 2009;378:73-9
34. Illum L. Nasal drug delivery: new developments and strategies. Drug Dev Tech 2002;7(23):1184-9 (Pubitemid 35430155)
35. Kumar M, Mishra A, Babbar AK, et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008;16(10):806-14
36. Bhise SB, Yadav AV, Avachat AM, et al. Bioavailability of intranasal drug delivery system. Asian J Pharm 2008;2:201-15
37. Berg MP, Verhoef C, Romeijn SG, et al. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 2004;58:131-5 (Pubitemid 38781013)
38. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 2001;51:5-19 (Pubitemid 32763069)
39. Kubik H, Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77 (Pubitemid 28044092)
40. Kumar M, Mishra A, Pathak K. Formulation and characterization nanoemulsion of olanzapine for intranasal delivery. PDA J Pharm Sci Technol 2009;63:501-11
41. Ying W. The nose may help the brain; intranasal drug delivery for treating neurological diseases. Future Neurol 2008;3(1):1-4
42. Bhumkar DR, Joshi HM, Sastry M, et al. Chitosan reduced gold nanoparticles as novel carriers for transdermal delivery of insulin. Pharm Res 2007;24:1415-27
43. Sarkar MA. Drug metabolism in nasal mucosa. Pharm Res 1992;9:1-9
44. Hermens W, Merkus F. The influence of drugs on ciliary movement. Pharm Res 1987;4:445-50
45. Wang YC, Zuo Z. Intranasal deliverymodification of drug metabolism and brain disposition. Pharm Res 2010;27:1208-23
46. Shao Z, Mitra AK. Bile salt-fatty acid mixed micelles as nasal absorption promoters. III. Effects on nasal transport and enzymatic degradation of acyclovir prodrugs. Pharm Res 1994;11:243-51
47. Stevens J, Suidgeest E, Graaf H, et al. A new minimal - stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharm Res 2009;26:1911-19
48. Kushwaha SKS, Keshari RK, Rai AK. Advances in nasal trans-mucosal drug delivery. J Appl Pharm Sci 2011;7:21-8
49. Csaba N, Fuentes MG, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009;61:140-57
50. Mahajan HS, Shah SK, Surana SJ. Nasal in situ gel containing hydroxyl propyl b-cyclodextrin inclusion complex of artemether: development and in vitro evaluation. J Incl Phenom Macrocyl 2010;16:1-10
51. Luppi B, Bigucci F, Abruzzo A, et al. Freeze-dried chotosan/pectin inserts for antipsychotic drug delivery. Eur J Pharm Biopharm 2001;75:381-7
52. Charlton S, Jones NS, Davis SS, et al. Distribution and clearance of bioadhesive formulations from the olfactory region in man: Effect of polymer type and nasal delivery device. Eur J Pharm Sci 2007;30:295-302
53. Chaudhari PV. Recent trends in nasal drug delivery - an overview. Pharmainf Net 2006;4:5.1-5
54. Mistry A, Stolnic S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57
55. Agu R, Dang HV, Jorissen M, et al. In-vitro polarized transport of L-phenylalanine in human nasal epithelium and partial characterization of of the amino acid transporters involved. Pharm Res 2003;20:1125-32 (Pubitemid 36951835)
56. Hussain AA. Intranasal drug delivery. Int J Pharm 1998;29:39-49 (Pubitemid 28044085)
57. Wang D, Gao EY, Yun EL. Study on brain targeting of ralititrexed following intranasal administration in rats. Cancer Chemother Phamacol 2006;57:57-104
58. Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24(9):1733-42
59. Yyas TK, Babbar AK, Sharma PK, et al. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsion of sumatriptan. AAPS PharmSciTech 2006;7(1):E1-9
60. Upadhyay S, Parikh A, Joshi P, et al. Intranasal drug delivery system- a glimpse to become maestro. J Appl Pharma Sci 2011;1:34-44
61. Vyas TK, Babbar AK, Sharma RK, et al. Intranasal mucoadhesive microemulsion of zolmitriptan: Preliminary studies on brain targeting. J Drug Target 2005;13(5):45-52
62. Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption. Eur J Pharm Biopharm 2008;70:735-40
63. Zhang Q, Jiang X, JiangW, et al. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004;275:85-96 (Pubitemid 38481522)
64. Mandal S, Mandal SD. Design and development of carbamazepine mucoadhesive microemulsion for intranasal drug delivery. Int J Pharm Sci Rev Res 2010;3:56-60
65. Vyas TK, Babbar AK, Sharma RK, et al. Intranasal mucoadhesive microemulsions of clonazepam preliminary studies on brain targeting. J Pharm Sci 2006;95:1-11